Prevention and mycoses in immunocompromised patients

Area of Science:

• Mycology
• Infectious Diseases
• Oncology

Background:

• Invasive fungal infections are serious complications in immunocompromised individuals, especially neutropenic cancer patients.
• Candidiasis and aspergillosis are prevalent, with poor prognoses and limited effective prophylactic strategies.
• Existing prophylactic agents like polyenes and imidazoles have controversial efficacy and potential resistance issues.

Purpose of the Study:

• To review the current status of prophylactic methods for invasive fungal infections in immunocompromised hosts.
• To evaluate the effectiveness and limitations of available antifungal agents and formulations.
• To identify potential strategies for preventing candidiasis and aspergillosis.

Main Methods:

• Literature review of studies evaluating prophylactic antifungal agents and methods.
• Analysis of data on the efficacy of polyenes, imidazoles, and other interventions.
• Consideration of emerging resistance patterns and alternative prevention techniques.

Main Results:

• No single regimen is currently recommended for preventing invasive candidiasis due to controversial data.
• Antifungal resistance (polyenes) and selection of resistant strains (imidazoles) are significant concerns.
• High-efficiency particulate air (HEPA) filtration and prophylactic nasal amphotericin B show promise for aspergillosis prevention.

Conclusions:

• Effective prophylaxis for invasive fungal infections in immunocompromised patients remains an unmet need.
• Further investigation into novel prophylactic approaches, including environmental controls and targeted therapies, is crucial.
• Careful consideration of antifungal resistance is necessary when selecting prophylactic strategies.